Clinical trials: Multi-cancer Early Detection
- Condition Multi-cancer Early Detection
- Funder type Industry (pharma, biotech, devices)
- Accepts healthy volunteers yes
Cancer, Early Detection of Cancer
Multi-canceR Early-detection Test in Asymptomatic Individuals (PREVENT)
PREVENT is a prospective, multicenter, interventional study evaluating the performance of the OverC multi-cancer detection blood test in asymptomatic individuals with cancer risk.
- Conditions
- Cancer, Early Detection of Cancer, Circulating Cell-free DNA
- Trial name
- PREVENT (NCT05227534)
- Testing
- OverC multi-cancer detection blood test
- Where
- China
- Volunteers
- 12,500 people, healthy volunteers welcome
- Sponsor
- Guangzhou Burning Rock Dx Co., Ltd.
Colorectal Cancer
Clinical Validation of An Optimized Multi-Target Stool DNA (Mt-sDNA 2.0) Test, for Colorectal Cancer Screening "BLUE-C"
The primary objective of this study is to assess the sensitivity for colorectal cancer (CRC) and specificity of the mt-sDNA 2.0 test.
- Trial name
- NCT04144738
- Testing
- mt-sDNA 2.0 screening test, FIT test, Colonoscopy
- Where
- 195 sites in United States
- Volunteers
- 26,758 people, healthy volunteers welcome
- Sponsor
- Exact Sciences Corporation
High Risk Cancer, Lung Cancer
Retrospective Clinical Trial Comparing Radiologists' Diagnosis Accuracy in Lung Cancer Screening Population With and Without the Help of an AI/ML Tech-based SaMD
This is a two arm, randomized, controlled, blinded, multi-case multi reader (MRMC), retrospective study for the evaluation of the efficacy and safety of an AI/ML technology-based CADe/x developed to detect, localize and…
- Trial name
- RELIVE (NCT06751576)
- Testing
- Median LCS
- Where
- 5 sites in United States, Spain
- Volunteers
- 480 people, healthy volunteers welcome
- Sponsor
- Median Technologies
Early Detection of Cancer, Cancer
PATHFINDER 2: A Multi-Cancer Early Detection Study
This is a prospective, multi-center interventional study of the GRAIL multi-cancer early detection (MCED) test with return of test results for participants enrolled through healthcare systems in North America.
- Trial name
- NCT05155605
- Testing
- Multi-Cancer Early Detection Test
- Where
- 56 sites in United States, Canada
- Volunteers
- 35,883 people, healthy volunteers welcome
- Sponsor
- GRAIL, Inc.
Cancer
Development and Validation of Harbinger Health Test for Early Cancer Detection
This is a prospective, multi-center, observational study with a collection of biospecimens and clinical data from approximately 10,000 participants from up to 125 clinical network sites and locations in the United States.
- Trial name
- CORE-HH (NCT05435066)
- Testing
- Harbinger Health Test
- Where
- 128 sites in United States
- Volunteers
- 8,038 people, healthy volunteers welcome
- Sponsor
- Harbinger Health
Cancer
a PROspective Case Control Study to Develop and Validate a Blood Test FOr mUlti-caNcers Early Detection（PROFOUND）
This study is a multi-center, case-control study aiming at developing and blinded testing machine learning-based multiple cancers early detection model by prospectively collecting blood samples from newly diagnosed cancer…
- Trial name
- PROFOUND (NCT06217900)
- Where
- 8 sites in China
- Volunteers
- 16,666 people, healthy volunteers welcome
- Sponsor
- Shanghai Weihe Medical Laboratory Co., Ltd.
Cancer
Assessment of the Implementation of an Investigational Multi-Cancer Early Detection Test Into Clinical Practice
PATHFINDER is a prospective, multi-center study in which approximately 6,200 participants will be enrolled. An investigational multi-cancer early detection test, developed by GRAIL, will be ordered by and results returned to a…
- Trial name
- NCT04241796
- Testing
- Multi-Cancer Early Detection Test
- Where
- 11 sites in United States
- Volunteers
- 6,662 people, healthy volunteers welcome
- Sponsor
- GRAIL, Inc.
Pancreatic Ductal Adenocarcinoma, Familial Pancreatic Cancer
A Study of IMMray™ PanCan-d Test for Early Detection of Pancreatic Cancer in High-risk Groups
PanFAM-1 is a clinical study for early detection of pancreatic cancer in high-risk groups. The goals of the study are to assess the performance and diagnostic accuracy of the IMMray™ PanCan-d test compared to standard-of-care…
- Conditions
- Pancreatic Ductal Adenocarcinoma, Familial Pancreatic Cancer, FAMMM - Familial Atypical Mole Malignant Melanoma Syndrome
- Trial name
- NCT03693378
- Where
- 21 sites in United States, Canada and 3 more
- Volunteers
- 1,349 people, healthy volunteers welcome
- Sponsor
- Immunovia, Inc.
Osteoporosis, Osteopenia
A Study Evaluating the Performance of Using AI Software and Chest X-rays to Screen for Osteoporosis as Compared to Standard DXA Scans in Patients 50 Years and Older
The goal of this study is to assess the performance of an artificial intelligence software (Osteo Signal) in detecting osteoporosis risk in adults 50 years and older.
- Trial name
- NCT07421713
- Testing
- Osteo Signal
- Where
- 3 sites in Netherlands, United Kingdom
- Volunteers
- 595 people, healthy volunteers welcome
- Sponsor
- Promedius Inc
Brain Cancer, Breast Cancer
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
This is an observational case-control study to train and validate a genome-wide methylome enrichment platform to detect multiple cancer types and to differentiate amongst cancer types.
- Conditions
- Brain Cancer, Breast Cancer, Bladder Cancer, Cervical Cancer
- Trial name
- CAMPERR (NCT05366881)
- Where
- 17 sites in United States
- Volunteers
- 7,000 people, healthy volunteers welcome
- Sponsor
- Adela, Inc
Early Detection of Cancer, Cancer
REFLECTION: A Clinical Practice Learning Program for Galleri®
REFLECTION is a multi-center, prospective, non-interventional, cohort study that will enroll approximately 14,000 individuals who have opted to be screened with Galleri®, a blood-based, multi-cancer early detection (MCED) test in…
- Trial name
- NCT05205967
- Testing
- MCED, SOC
- Where
- 16 sites in United States
- Volunteers
- 14,633 people, healthy volunteers welcome
- Sponsor
- GRAIL, Inc.
Lung Cancer, Colorectal Cancer
ProSight: A Multi-centre Interventional Study Evaluating MCED in Asymptomatic Population
This is a prospective, multi-centre interventional study evaluating the feasibility of blood-based multi-cancer early detection test in asymptomatic screening cohort.
- Conditions
- Lung Cancer, Colorectal Cancer, Liver Cancer, Grastic Cancer
- Trial name
- NCT06790355
- Testing
- multi-cancer early detection
- Where
- 4 sites in China
- Volunteers
- 2,527 people, healthy volunteers welcome
- Sponsor
- Shanghai Weihe Medical Laboratory Co., Ltd.
Stomach Cancer
Development of Free DNA Multi-target Methylated PCR for Auxiliary Diagnosis of Gastric Cancer
This was a case control, non-intervention study jointly developed by Fudan University Cancer Hospital and Shanghai Singlera Genomics Company.
- Trial name
- NCT05336058
- Testing
- No intervention
- Where
- China
- Volunteers
- 1,140 people, healthy volunteers welcome
- Sponsor
- Singlera Genomics Inc.
Neoplasms, Cancer
The STRIVE Study: Development of a Blood Test for Early Detection of Multiple Cancer Types
GRAIL is using high-intensity sequencing of circulating cell-free nucleic acids (cfNAs) to develop blood tests to detect cancer early.
- Trial name
- NCT03085888
- Where
- 35 sites in United States
- Volunteers
- 99,481 people, healthy volunteers welcome
- Sponsor
- GRAIL, Inc.
Trisomy 21 and Other Fetal Aneuploidy
Automated Screen for Fetal Aneuploidy
The purpose of this study is to develop and evaluate a blood test and automated microfluidic test platform for the prenatal screening of fetal aneuploidy.
- Trial name
- FAST1 (NCT03635359)
- Testing
- blood test
- Where
- 6 sites in Australia, Belgium and 4 more
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- BioCeryx
Colo-rectal Cancer, Cancer Colon
AI-EMERGE: Development and Validation of a Multi-analyte, Blood-based Colorectal Cancer Screening Test
Freenome is using a type of artificial intelligence, called machine learning, to identify patterns of cell-free biomarkers in blood to detect cancer early.
- Conditions
- Colo-rectal Cancer, Cancer Colon, Cancer, Rectum, Neoplasms,Colorectal
- Trial name
- NCT03688906
- Where
- 30 sites in United States, Canada
- Volunteers
- 3,275 people, healthy volunteers welcome
- Sponsor
- Freenome Holdings Inc.
Cancer
LEVANTIS-0093A: GAGomes for Multi-Cancer Early Detection in High-Risk Adults (LEV93A)
LEVANTIS-0093A (LEV93A) is a prospective cohort observational clinical study to validate the plasma free GAGome MCED test in adults at high risk of developing cancer ("high-risk adults"), specifically in 55-80-year-old adults…
- Trial name
- LEV93A (NCT05295017)
- Where
- United Kingdom
- Volunteers
- 1,235 people, healthy volunteers welcome
- Sponsor
- Elypta
Human Papilloma Virus, Human Papilloma Virus Related Cervical Carcinoma
Validation of Vaginal Self-Sampling With the Abbott Multi-Collect Swab for HPV Screening in Women Aged 30 to 64 Years
This study evaluates the performance of HPV testing on vaginal self-collected samples obtained with the Abbott Multi-Collect device.
- Conditions
- Human Papilloma Virus, Human Papilloma Virus Related Cervical Carcinoma, Cervical Carcinoma
- Trial name
- VALMUDES (NCT07768787)
- Testing
- Abbott Multi-Collect Specimen Collection Swab
- Where
- Belgium
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- AML
Gastric Cancer
Gastric Cancer Early Detection by Multi-dimensional Analysis of cfDNA
To facilitate the early gastric cancer diagnosis, an assay based on assessing large-scale methylation and fragmentation profiles of the plasma cell free (cfDNA) will be developed and validated.
- Trial name
- NCT05668910
- Testing
- whole genomic methylation and fragmentation profile analysis of cfDNA
- Where
- China
- Volunteers
- 360 people, healthy volunteers welcome
- Sponsor
- GeneCast Biotechnology Co., Ltd.
Colorectal Neoplasms, Digestive System Diseases
Multi-Target Colorectal Cancer Screening Test for the Detection of Colorectal Advanced Adenomatous Polyps and Cancer
The primary objective is to determine the sensitivity and specificity of the Exact Colorectal Cancer (CRC) screening test for colorectal cancer, using colonoscopy as the reference method.
- Conditions
- Colorectal Neoplasms, Digestive System Diseases, Colonic Diseases, Colorectal Cancer
- Trial name
- DeeP-C (NCT01397747)
- Where
- 184 sites in United States, Canada
- Volunteers
- 12,776 people, healthy volunteers welcome
- Sponsor
- Exact Sciences Corporation